News headlines about Epizyme (NASDAQ:EPZM) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Epizyme earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.4892331844753 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern’s rankings:

EPZM has been the subject of several recent research reports. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research note on Wednesday, July 12th. Cann reaffirmed a “buy” rating and set a $26.00 target price on shares of Epizyme in a research report on Wednesday, June 21st. ValuEngine raised Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. BidaskClub cut Epizyme from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating and set a $20.00 target price on shares of Epizyme in a research report on Friday, September 15th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Epizyme has a consensus rating of “Buy” and a consensus price target of $23.78.

Shares of Epizyme (EPZM) opened at 17.60 on Wednesday. The firm’s market cap is $1.03 billion. The stock’s 50 day moving average price is $17.81 and its 200-day moving average price is $15.45. Epizyme has a 52-week low of $8.38 and a 52-week high of $20.45.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.08. The business had revenue of $10.00 million for the quarter, compared to the consensus estimate of $3.95 million. During the same quarter in the previous year, the company earned ($0.49) EPS. The firm’s revenue for the quarter was up 2027.7% on a year-over-year basis. On average, analysts forecast that Epizyme will post ($2.36) EPS for the current year.

In other news, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $16.81, for a total value of $252,150.00. Following the completion of the transaction, the insider now directly owns 23,123 shares of the company’s stock, valued at $388,697.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David M. Mott purchased 200,000 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was bought at an average cost of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at $91,500. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 45,000 shares of company stock valued at $688,950. 25.20% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Epizyme (EPZM) Getting Somewhat Positive Media Coverage, Analysis Finds” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/18/epizyme-epzm-getting-somewhat-positive-media-coverage-analysis-finds.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Insider Buying and Selling by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.